Journal: The Journal of Biological Chemistry
Article Title: Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway
doi: 10.1016/j.jbc.2022.102056
Figure Lengend Snippet: Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist DY268 (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.
Article Snippet: DY268 (FXR antagonist) was from Axon Medchem.
Techniques: Gene Expression, Control